{"disease":{"id":"allogeneic-hematopoeitic-stem-cell-transplantation","name":"allogeneic hematopoeitic stem cell transplantation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03384225","title":"CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03384212","title":"CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}